CARDIOPROGRESS
Foundation for the advancement of cardiology

Europe to personalise prevention of second heart attacks Cardiovascular disease (CVD) is the top cause of death in Europe and worldwide, accounting for 47% of deaths in women and 39% of deaths in men.1 CVD costs the EU more than €210 billion a year,2 a sum expected to escalate with an ageing population and the cost of novel therapies.

Eating meat, including chicken, linked to heart disease risk in study Eating meat has been linked to heart disease in the latest study to suggest the food could pose some risk to our health.

Periodontitis increases the risk of suffering from future atherosclerotic cardiovascular disease It was already known, but so far there was no rigorous and exhaustive report that corroborated the link between periodontitis and the future risk of developing atherosclerotic cardiovascular disease. Now two of the international reference entities in the field of periodontal and cardiovascular health, the European Federation of Periodontics (VET) and the World Heart Federation (WHF), publish a consensus powerful that leaves no room for doubt.

PARTNER 2A Intermediate-Risk TAVR Five-Year Results Hit Print Late outcomes of transcatheter aortic valve replacement (TAVR) in the PARTNER 2A trial are now enshrined in the peer-reviewed literature.

New report reveals the role of physical activity in preventing and treating cardiovascular diseases The European Heart Network, in collaboration with the WHO European Office for the Prevention and Control of Noncommunicable Diseases, has published an important report on physical activity policies for cardiovascular health. Each year, cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. Physical inactivity increases the risk of cardiovascular diseases by more than 20%.

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.

Ticagrelor Sans Aspirin Trial Answers Some Questions About DAPT Hi. My name is Robert Byrne. I'm an interventional cardiologist at the German Heart Center in Munich and am here at TCT 2019 in San Francisco, where we've seen some interesting results from the TWILIGHT study. I would like to discuss some of the implications of this study for clinical practice.

From Naysayer to Convert: Cardiologists Should Prescribe SGLT2 Inhibitors Сardiologists have largely resisted calls to get more involved in diabetes. The comments on the Medscape article "Cardiologists Must Get Up to Speed on Treating Diabetes" echoed the sentiments of many regarding sodium-glucose contransporter-2 (SGLT2) prescribing.

MITRA-FR at 2 Years: MitraClip Still No Better Than Med Therapy Patrice Wendling PARIS — An additional year of follow-up in the MITRA-FR trial confirm no added benefit of percutaneous repair of functional mitral regurgitation (MR) with the MitraClip (Abbott) compared with optimal medical therapy alone.

Daily Aspirin May Lower Risk for Fatty Liver Progression Taking daily aspirin may prevent progression of nonalcoholic fatty liver disease (NAFLD) to liver fibrosis and nonalcoholic steatopepatitis (NASH), according to a study published online May 8 in Clinical Gastroenterology and Hepatology.

ESC Issues First Comprehensive Cardiomyopathy Guidelines The European Society of Cardiology has released new guidelines for cardiomyopathies, their first major comprehensive international guidelines to address diagnosis and treatment of the broad causes of heart muscle dysfunction.

AHA/ACC Issue Updated Chronic Coronary Disease Guidelines The latest clinical practice guideline for managing patients with chronic coronary disease (CCD) takes an evidence-based and patient-centered approach to care and includes key updates on revascularization, beta-blocker use, and routine functional and anatomic testing. Developed by the American Heart Association (AHA), the American College of Cardiology (ACC), and other specialty societies, the 2023 guideline both updates and consolidates ACC/AHA guidelines previously published in 2012 and 2014 for the management of patients with stable ischemic heart disease.

Russian national congress of cardiology 2019

FDA Clears Architect Stat High-Sensitivity Troponin Test for MI The US Food and Drug Administration (FDA) has approved the Architect Stat (Abbott Laboratories) high-sensitivity troponin-I assay, which can detect myocardial infarction (MI) faster and more accurately than other troponin tests, according to the company.

World Heart Day 2019 This year on World Heart Day, as part of our mission to ensure heart health equity for all, we want to create a global community of Heart Heroes … people from all walks of life who are acting now to live longer, better, heart-healthy lives by making a promise: for MY HEART, for YOUR HEART, for ALL OUR HEARTS.

ESC 2019: Wrap up in Russian - Live and interactive programme In collaboration with the Russian Society of Cardiology, this programme is designed to present a selection of scientific highlights from ESC Congress and discuss clinical practice implications with experts.

ESC Congress 2019 together with World Congress of Cardiology ESC Congress 2019 together with World Congress of Cardiology Saturday 31 August - Wednesday 4 September 2019 Paris - France

Announcement of the European Congress of Cardiology From August 31 to September 4, 2019, he Congress of the European Society of Cardiology in conjunction with the World Congress of Cardiology - will be held in Paris (France).

Trial Evaluating Sacubitril/Valsartan for HFpEF Misses Primary End Point Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).

ESC Congress 2019 together with World Congress of Cardiology Full detailed data from PARAGON-HF will be presented at the ESC Congress 2019 in September. Novartis announced topline results from the phase 3 PARAGON-HF study evaluating the safety and efficacy of sacubitril/valsartan (Entresto) in heart failure patients with preserved ejection fraction (HFpEF).